Dongcheng International Pharmaceutical Innovation Application Base project is important for the Group to promote the future development of the nuclear medicine. Since the start of the project, it has made rapid progress and has received widespread attention and expectations from all sectors. Recently, “Yantai News” focused on the construction of the Blue Medicine Valley Life Island project and provided a detailed introduction to the LNC innovative drugs.

As one of the first batch of projects, LNC Muping project has basically completed interior decoration and some instruments and equipment have begun to be installed and commissioned. 

LNC was jointly founded by DC PHARMA and Professor Chen Xiaoyuan, a top expert in molecular imaging and nanomedicine, in 2021. Adhering to the concept of "Innovation-driven Micro Radiotheranostics R&D, Benefit People from Precision Therapy", LNC is focusing on the construction of a globally leading integrated diagnosis and therapy innovation platform on cancer nuclear medicine R&D. Next, LNC will continue to rely on DC PHARMA's strong and sound production and research system for the entire nuclear medicine industry chain, strengthen innovation, providing precision diagnosis and therapeutic methods for cancer patients and promoting the development of nuclear medicine in the world.

In addition to the LNC Muping project, the DC PHARMA is also accelerating the construction of more than ten projects on the Blue Medicine Valley Life Island. In the next step, the DC PHARMA will rely on the International Medical Innovation Application Base project to assist Yantai in building a core gathering area for the isotope and radiopharmaceutical industry in Northeast Asia, and contribute to the development of Yantai's pharmaceutical industry.